DSP Development

Efficiency is the key for a good downstream process to obtain consistently a pure and high quality product while recovering as much target protein as possible. Celonic has set up a downstream platform process for antibodies, often recovering more than 75% of the target mAB. This saves considerable development time and costs.

In addition, our experience in process development for non-antibody products enables us to maximize the product recovery during platform adaptation.

  • Adaption of state-of-the-art purification processes for mABs
  • Process development for non-antibody products
  • Process intermediate stability studies
  • Virus clearance studies
  • Extensive experience in purifying products from in-house CHOvolution™ and the human GEX® cell line